Paliperidone-induced neuroleptic malignant syndrome: A case report

Gonca Ayse Unal1

  • 1Clinic of Psychiatry, Mersin Sehir Egitim ve Arastirma Hastanesi, Toroslar, Mersin, Turkey.

Medicine
|March 11, 2025
PubMed
Abstract

Insights

Neuroleptic malignant syndrome (NMS) is a rare but serious complication of antipsychotic medications. This case study highlights NMS in a patient treated with long-acting injectable paliperidone, emphasizing the need for clinical vigilance.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Neuroleptic malignant syndrome (NMS) is a critical, potentially fatal adverse reaction to neuroleptic medications.
  • Paliperidone, an atypical antipsychotic, is used for schizophrenia treatment.
  • Limited data exists on NMS incidence with long-acting injectable (LAI) antipsychotics, necessitating further case studies.

Purpose of the Study:

  • To report a case of NMS in a patient receiving LAI paliperidone.
  • To contribute to understanding NMS associated with LAI atypical antipsychotics.

Main Methods:

  • A 63-year-old male with schizophrenia presented with fever, muscle rigidity, and altered consciousness 2 days post-LAI paliperidone initiation.
  • Clinical examination revealed fever (39.5°C), tremors, rigidity, confusion, and elevated creatine kinase (1895 U/L).
  • Diagnosis of NMS was confirmed through clinical presentation and laboratory findings.

Main Results:

  • The patient received bromocriptine and amisulpride for 13 days.
  • Significant improvement in delirium and stabilization of vital signs were observed.
  • Laboratory markers normalized, and the patient was discharged after 14 days.

Conclusions:

  • NMS is a rare but critical emergency associated with antipsychotic use, including atypical agents like paliperidone.
  • Clinicians must maintain a high index of suspicion for NMS in patients on atypical antipsychotics, especially LAI formulations.
  • Prompt recognition and treatment are crucial for managing NMS and preventing mortality.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
106
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
115
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K